JP2020524167A5 - - Google Patents

Download PDF

Info

Publication number
JP2020524167A5
JP2020524167A5 JP2019570568A JP2019570568A JP2020524167A5 JP 2020524167 A5 JP2020524167 A5 JP 2020524167A5 JP 2019570568 A JP2019570568 A JP 2019570568A JP 2019570568 A JP2019570568 A JP 2019570568A JP 2020524167 A5 JP2020524167 A5 JP 2020524167A5
Authority
JP
Japan
Prior art keywords
cells
medicament according
subject
merkel cell
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019570568A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524167A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/038312 external-priority patent/WO2018236890A1/en
Publication of JP2020524167A publication Critical patent/JP2020524167A/ja
Publication of JP2020524167A5 publication Critical patent/JP2020524167A5/ja
Pending legal-status Critical Current

Links

JP2019570568A 2017-06-20 2018-06-19 Nk−92細胞とil−15アゴニストの併用療法 Pending JP2020524167A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762522319P 2017-06-20 2017-06-20
US62/522,319 2017-06-20
PCT/US2018/038312 WO2018236890A1 (en) 2017-06-20 2018-06-19 Nk-92 cells and il-15 agonist combination therapy

Publications (2)

Publication Number Publication Date
JP2020524167A JP2020524167A (ja) 2020-08-13
JP2020524167A5 true JP2020524167A5 (enExample) 2021-09-30

Family

ID=62875319

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019570568A Pending JP2020524167A (ja) 2017-06-20 2018-06-19 Nk−92細胞とil−15アゴニストの併用療法

Country Status (9)

Country Link
US (1) US20200121720A1 (enExample)
EP (1) EP3641799A1 (enExample)
JP (1) JP2020524167A (enExample)
KR (1) KR20200017495A (enExample)
CN (1) CN110740747A (enExample)
AU (1) AU2018288715A1 (enExample)
CA (1) CA3066465A1 (enExample)
IL (1) IL270840A (enExample)
WO (1) WO2018236890A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022250312A1 (ko) * 2021-05-27 2022-12-01 (주)에스엠티바이오 신경내분비종양의 치료용 자연살해세포

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1690927A1 (en) 1997-04-30 2006-08-16 Hans Klingemann Natural killer cell lines and methods of use
WO2005085282A1 (en) 2004-02-27 2005-09-15 Inserm (Institut National De La Sante Et De La Recherche Medicale) Il-15 binding site for il15-ralpha and specific il-15 mutants having agonists/antagonists activity
AU2008253720B2 (en) 2007-05-11 2014-01-16 Altor Bioscience Corporation Fusion molecules and IL-15 variants
WO2012040323A2 (en) 2010-09-21 2012-03-29 Altor Bioscien Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same

Similar Documents

Publication Publication Date Title
MY201603A (en) Combination of dextromethorphan and bupropion for treating depression
JP2014528901A5 (enExample)
JP2013533858A5 (enExample)
JP2018526460A5 (enExample)
RU2013123646A (ru) Комбинированная композиция
JP2015532293A5 (ja) 糖尿病患者における心不全の治療用組成物
SA522432668B1 (ar) طرق لعلاج سرطان الرئة للخلايا الصغيرة بصيغ من لوربينيكتيدين
RU2015116264A (ru) Композиции и способы лечения сердечной недостаточности у пациентов с диабетом
JP2018172440A5 (enExample)
MY204827A (en) Semaglutide in medical therapy
DE602005009176D1 (de) Behandlung von t-zellen-lymphom mittels 10-propargyl-10-deazaaminopterin
JP2020536923A5 (enExample)
JP2020524164A5 (enExample)
JP2020524167A5 (enExample)
WO2017142871A8 (en) Methods comprising fixed intermittent dosing of cediranib
MX2021008986A (es) Metodos de tratamiento de un paciente con enfermedad de parkinson.
JP2018516920A5 (enExample)
JP2018522881A5 (enExample)
JP2005529152A5 (enExample)
RU2023102211A (ru) Схемы дозирования иммуноконъюгата anti-folr1
Cummins et al. Sorafenib priming may augment salvage chemotherapy in relapsed and refractory FLT3-ITD-positive acute myeloid leukemia
NZ781127A (en) Mirikizumab for use in a method of treating crohn’s disease
MX2021003288A (es) Medicacion para aliviar los sintomas de la neuropatia periferica causada por farmacos anticancerigenos y/o suprimir el inicio de la neuropatia periferica.
NZ767902A (en) Methods of treating ulcerative colitis
MINGRINO et al. EFFECTS OF METHYL-PREDNISOLONE CLINICAL AND RADIOLOGICAL EVALUATION